BioSyent (CVE:RX) Share Price Crosses Above Fifty Day Moving Average – What’s Next?
by Michael Walen · The Markets DailyShares of BioSyent Inc. (CVE:RX – Get Free Report) crossed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of C$14.49 and traded as high as C$15.25. BioSyent shares last traded at C$15.25, with a volume of 385 shares traded.
BioSyent Stock Performance
The company has a debt-to-equity ratio of 11.66, a current ratio of 1.89 and a quick ratio of 6.91. The company has a fifty day moving average price of C$14.49 and a 200 day moving average price of C$14.56. The stock has a market cap of C$172.81 million, a P/E ratio of 19.45 and a beta of 1.00.
Insider Buying and Selling at BioSyent
In other BioSyent news, Director Seyed Ahmad Ashrafi sold 1,884 shares of BioSyent stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of C$14.65, for a total transaction of C$27,600.60. Following the completion of the transaction, the director owned 37,261 shares in the company, valued at approximately C$545,873.65. The trade was a 4.81% decrease in their position. In the last quarter, insiders have sold 4,358 shares of company stock valued at $63,132. Corporate insiders own 33.65% of the company’s stock.
BioSyent Company Profile
BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis.